SV Life Sciences Promotes LaViolette to Partner

SV Life Sciences said Thursday that it has promoted Paul LaViolette to partner. LaViolette joined SV Life Sciences, a VC firm, in 2009 as a venture partner.

PRESS RELEASE

SV Life Sciences (“SVLS”) today announced the promotion of Paul LaViolette to Partner. Mr. LaViolette joined SVLS in early 2009 as Venture Partner.
“Since joining SVLS, Paul has successfully applied his tremendous experience with large-scale medical technology businesses to our portfolio of development stage companies,” said David Milne, SVLS Managing Partner. “In doing so, Paul has underscored a key component to the SVLS value proposition. Consistently, we have attracted highly talented healthcare operators and executives from the life sciences fields and made them long-term members of our investment team. I know I speak on behalf of the entire firm in congratulating Paul on his promotion.”
At SVLS, Mr. LaViolette has attracted novel deal flow that has led to multiple new investments and investment options. He has assumed board and advisory roles for a number of existing SVLS portfolio companies including TransEnterix, CardioFocus, ValenTx, MindFrame and Altura Medical. In addition to these positions, he serves on the boards of Cameron Health, Conceptus, DC Devices, Direct Flow Medical, DJO Global, Thoratec, Trans 1, and the Medical Device Manufacturers Association (MDMA), giving him broad and ongoing exposure to the medical device and technology industries.
Mr. LaViolette has 30 years of global medical technology marketing and general management experience. Most recently, he was with Boston Scientific Corporation, where he served as COO, Group President, President-Cardiology and President-International. During his tenure, the Company grew revenues over 20 times. He also spearheaded over 20 acquisitions and led extensive product development, operations and worldwide commercial organizations. Prior to that, he held marketing and general management positions at CR Bard and various marketing roles at Kendall (Covidien). Mr. LaViolette has also served on the boards of Urologix, Percutaneous Valve Technologies and Advamed. He received his BA in Psychology from Fairfield University and his MBA from Boston College.
Mr. LaViolette is a member of SVLS’ team of 32 professionals organized according to experience and specialization into three practice areas: Biotechnology / Biopharmaceuticals; Medical Devices / Instrumentation; and Healthcare Services. These individuals’ diverse and complimentary skill sets and experiences enable SVLS to tailor an investment team for almost any life science business. Typically, SVLS recruits operating executives, called Venture Partners, who have distinguished careers in the life sciences fields and can bring extensive operating expertise to the SVLS portfolio of investments. They assist in sourcing, building and exiting investments successfully. When possible, these individuals are promoted to serve as Partners and ultimately as Managing Partners within the Firm. SVLS employs a close symbiosis between operating and financial professionals which has led to significant success over five investment funds.
About SV Life Sciences
SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages five venture capital funds and a publicly traded investment trust with approximately $2 billion of capital under management. The Firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco. For more information, please visit the company’s website at http://www.svlsa.com.